纖維肌痛治療市場：按藥物類別（抗抑鬱藥、抗癲癇藥、肌肉鬆弛劑、鎮痛藥等）、按分銷渠道、按地區分類 - 2022-2030 年的規模、份額、前景、機會分析

纖維肌痛是一種常見且複雜的慢性疼痛疾病，可導致肌肉骨骼疼痛、疲勞和局部壓痛，並帶來心理、身體和社會後果。纖維肌痛主要是由遺傳條件引起的，但確切原因尚不清楚。纖維肌痛最常見的症狀是疲勞、睡眠困難、慢性肌肉疼痛和壓痛點。其他症狀包括頭痛、肌肉酸痛、燒灼感、痙攣、緊繃感、注意力不集中、疲勞和抑鬱。纖維肌痛症狀可能會隨著時間的推移而累積，並且可能是由多種外部因素引起的。纖維肌痛的治療包括治療、藥物、有規律的有氧運動和減壓。此外，纖維肌痛治療開出抗抑鬱藥和止痛藥來治療抑鬱、焦慮、疼痛和疲勞。FM/a 測試是用於診斷纖維肌痛的血液測試。無論年齡大小，它都可以用於至少有四種典型纖維肌痛症狀的患者。有三種專門批准用於纖維肌痛的藥物：度洛西汀（Cymbalta）、米那普崙（Sabella）和普瑞巴林（Lyrica）。非處方止痛藥用於治療纖維肌痛。像阿片類藥物這樣的強效藥物不是長期使用的，而且會讓人上癮。

市場動態

市場上的主要參與者正專注於開發治療纖維肌痛的新型藥物的研發活動。在纖維肌痛治療市場推出新藥預計將在預測期內推動纖維肌痛治療市場的增長。

例如，2018 年 12 月，Aptinyx Inc., Biotech Company宣布了對 NYX-2925 的探索性研究的中期分析的積極結果，NYX-2925 是一種新型 NMDA 受體 (NMDAr) 調節劑，用於纖維肌痛患者。研究中的受試者接受兩種劑量水平的 NYX-2925、20mg 和 200mg，以及每天口服安慰劑，持續六週。

2017 年，Virios Therapeutics, Biotechnology company宣布，《Journal of Pain Research》公佈了 IMC-1 治療纖維肌痛的 2 期 PRID-201 試驗的關鍵頂線結果。這項為期 16 週的隨機、雙盲、安慰劑對照試驗在 12 個美國研究中心進行，招募了 143 名 ACR2010 標准定義的纖維肌痛患者。在 PRID-201 試驗中，隨機分配至 IMC-1（celecoxib+famciclovir）的患者與隨機分配至安慰劑的患者相比，纖維肌痛相關疼痛明顯減輕。

此外，過去幾年，Sun Pharmaceutical Industries、Mylan NV 和 Teva Pharmaceuticals Industries 等主要仿製藥製造商推出了治療纖維肌痛的仿製藥。

此外，2021 年 9 月，阿拉巴馬大學伯明翰分校進行了一項研究，以評估右美沙芬 (DXM) 是否能減輕纖維肌痛 (FM) 的疼痛。右美沙芬 (DXM) 是一種在一些非處方產品中發現的藥物，包括止咳藥。這種藥物可以通過抑制中樞神經系統的炎症來減輕纖維肌痛 (FM) 的疼痛。右美沙芬（DXM）仍處於第二階段試驗。

本次調查的主要特點

• 本報告對全球纖維肌痛治療市場進行了深入分析，展示了以 2021 年為基準年的預測期間（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
• 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資主張矩陣。
• 它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景和主要參與者採用的競爭戰略的關鍵見解。
• 根據公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數對全球纖維肌痛治療市場的主要參與者進行了分析。
• 本研究涉及的主要公司包括Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
• 本報告中的見解將使營銷人員和公司管理層能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 全球纖維肌痛治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球纖維肌痛治療市場的各種戰略矩陣來促進他們的決策。

目錄

第一章研究目的和前提條件

• 研究目標
• 先決條件
• 縮寫的解釋

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場快照：按藥物類別
  • 市場快照：按分銷渠道
  • 市場快照：按地區
• 連貫的機會地圖 (COM)

第三章市場動態、法規及趨勢分析

• 市場動態
  • 司機
  • 抑製劑
  • 市場機會
• 影響分析
• 管道分析
• 專利訴訟
• 保險報銷
• 專利格局（ANDA/NDA 情報）
• PEST分析
• 搬運工分析

第 4 章全球纖維肌痛治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府的努力
• COVID-19 的市場影響

5 2017-2030 年按藥物類別分列的纖維肌痛治療劑全球市場

• 抗抑鬱藥
• 米那普崙（Sabella，其他仿製藥）
• 度洛西汀（Cymbalta，其他仿製藥）
• 其他
• 抗癲癇藥
• 普瑞巴林（Lyrica，其他仿製藥）
• 其他
• 肌肉鬆弛劑
• 止痛藥
• 其他（包括管道藥品）

6按分銷渠道分列的全球纖維肌痛治療市場：2017-2030

• 醫院藥房
• 零售藥店
• 網上藥店

7 2017-2030 年按地區分列的纖維肌痛治療劑全球市場

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 亞太其他地區
• 中東
• 海合會
• 以色列
• 中東其他地區
• 非洲
• 北非
• 中非
• 南非

第 8 章 競爭格局

• 熱圖分析
• 公司簡介
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Novartis AG
  • Allergan plc
  • Sun Pharmaceutical Industries Ltd.
  • Aptinyx, Inc.
  • Prismic Pharmaceuticals, Inc.
  • Innovative Med Concepts, Inc.
  • Intec Pharma Ltd
  • Astellas Pharma Inc.

第 9 章

• 參考
• 調查方法

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, muscle pain, burning, twitching, or tightness, poor concentration, draining fatigue and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for the treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue. The FM/a Test is a blood test used for the diagnosis of fibromyalgia. It is available for use in patients of any age who have at least four of the typical symptoms of fibromyalgia. The three drugs approved specifically for fibro pain are Duloxetine (Cymbalta), Milnacipran (Savella), Pregabalin (Lyrica). Over-the-counter painkillers are used in treating fibromyalgia. Stronger medicines, like opioids,are not prescribed for long term use, and you could become dependent on them.

Market Dynamics

Key players in the market are focusing on research and development activities for the development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period.

For instance, in December 2018, Aptinyx Inc., Biotech Company announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2017, Virios Therapeutics, Biotechnology company announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. launched generic drugs for fibromyalgia treatment in the market.

Furthermore, in September 2021, University of Alabama at Birmingham, carried out a study to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. Dextromethorphan (DXM) is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce Fibromyalgia (FM) pain by suppressing inflammation in the central nervous system. The Dextromethorphan (DXM) is still in phase 2 trial.

Key features of the study:

• This report provides an in-depth analysis of the global fibromyalgia treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fibromyalgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibromyalgia treatment market

Detailed Segmentation:

• Global Fibromyalgia Treatment Market, By Drug Class:
  • Antidepressants
    • Milnacipran (Savella and Other Generics)
    • Duloxetine (Cymbalta and Other Generics)
    • Others
  • Antiepileptics
    • Pregabalin (Lyrica and Other Generics)
    • Others
  • Muscle Relaxants
  • Analgesics
  • Others (Including Pipeline Drugs)
• Global Fibromyalgia Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Fibromyalgia Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Eli Lilly and Company*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer, Inc.
  • Novartis AG
  • Allergan plc.
  • Sun Pharmaceutical Industries Ltd.
  • Aptinyx, Inc.
  • Prismic Pharmaceuticals, Inc.
  • Innovative Med Concepts, Inc.
  • Intec Pharma Ltd.
  • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Pipeline Analysis
• Patent Litigations
• Reimbursement
• Patent Landscape (ANDA/NDA Intelligence)
• PEST Analysis
• Porter's Analysis

4. Global Fibromyalgia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Fibromyalgia Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Antidepressants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Segment Trends
• Milnacipran (Savella and Other Generics)
• Duloxetine (Cymbalta and Other Generics)
• Others
• Antiepileptics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Segment Trends
• Pregabalin (Lyrica and Other Generics)
• Others
• Muscle Relaxants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Analgesics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Including Pipeline Drugs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Fibromyalgia Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Fibromyalgia Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Eli Lilly and Company
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Pfizer, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Novartis AG
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Allergan plc
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Aptinyx, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Prismic Pharmaceuticals, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Innovative Med Concepts, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Intec Pharma Ltd
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies
  • Astellas Pharma Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Market Strategies

9. Section

• References
• Research Methodology
• About Us and Sales Contact